For the FDA to approve a psychedelic as medicine, companies must prove in large clinical trials that the drug works better than a placebo — and that's genuinely hard to do with psychedelics because participants almost always know whether they got the real drug. That unsolved problem, plus the slow pace of trials, means no psychedelic medicine lands on pharmacy shelves in 2026.
Unresolved blinding and expectancy-bias problems block approval; no NDA is positioned for a 2026 decision. FDA actions therefore stay procedural rather than substantive.